<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01641094</url>
  </required_header>
  <id_info>
    <org_study_id>ETIM</org_study_id>
    <nct_id>NCT01641094</nct_id>
  </id_info>
  <brief_title>Effect of Teleprevir in Triple Therapy on Intrahepatic Immunological Mechanisms</brief_title>
  <acronym>ETIM</acronym>
  <official_title>Effect of Telaprevir in Triple Therapy on Intrahepatic Immunological Mechanisms.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foundation for Liver Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen-Cilag B.V.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Foundation for Liver Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic hepatitis C infection (HCV) is a disease that affects worldwide about 170 million&#xD;
      people. The previous standard of care therapy of chronic HCV patients consists of&#xD;
      pegylated-IFN-α combined with ribavirin, and results in sustained clearance of HCV-RNA in&#xD;
      only about 50% of the HCV genotype 1 infected patients. Telaprevir, a NS3A-4A inhibitor, has&#xD;
      previously proven to offer therapeutic options to previous non-responders to the standard of&#xD;
      care. Although, not all chronic HCV patients benefit from telaprevir and it is still not&#xD;
      known why certain patients are also non-responsive to this triple therapy. In this study we&#xD;
      try to understand why certain patients are also non-responsive to telaprevir, how triple&#xD;
      therapy modulates the responsiveness to IFN-α and what the immunological consequences are of&#xD;
      treatment with telaprevir, either directly or as a result of telaprevir-induced reduction of&#xD;
      HCV-RNA levels.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determine functionality of immune cells in the liver and blood in chronic HCV patients before, during and after treatment with telaprevir, pegylated-IFN-a and ribavirin</measure>
    <time_frame>24 week follow-up</time_frame>
    <description>By looking at T cells, NK cells and monocytes during triple therapy, as well intrahepatic as in peripheral blood, we try to better understand why some patients respond and others do not respond to therapy.</description>
  </primary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic hepatitis C, genotype 1&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients between 18 and 70 years of age, with a chronic hepatitis C - genotype 1&#xD;
             infection&#xD;
&#xD;
          -  Patients are naive, non-responders or relapsers to previous treatment with&#xD;
             peginterferon or conventional interferon plus ribavirin combination therapy&#xD;
&#xD;
          -  High viral load (&gt;400,000 IU/ml)&#xD;
&#xD;
          -  Indication for antiviral therapy of hepatitis C according to current clinical&#xD;
             guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Decompensated cirrhosis (Child-Pugh Grade B or C)&#xD;
&#xD;
          -  Hepatic imaging (ultrasound, CT or MRI) with the evidence of hepatocellular carcinoma.&#xD;
&#xD;
          -  Females who are pregnant or breast-feeding&#xD;
&#xD;
          -  History or other evidence of severe illness, malignancy or any other condition which&#xD;
             would make the patient, in the opinion of the investigators, unsuitable for the study&#xD;
&#xD;
          -  Co-infections with human immunodeficiency virus (HIV) or Hepatitis B virus (HBV)&#xD;
&#xD;
          -  Presence of contra-indications for antiviral therapy with telaprevir:&#xD;
&#xD;
          -  Telaprevir is contraindicated when combined with drugs that are highly dependent on&#xD;
             CYP3A for clearance and for which elevated plasma concentrations are associated with&#xD;
             serious and/or life-threatening events. Telaprevir in contraindicated when combined&#xD;
             with drugs that strongly induce CYP3A and thus may lead to lower exposure and loss of&#xD;
             efficacy of Telaprevir. The contraindicated medications include the following:&#xD;
&#xD;
          -  Alfuzosin&#xD;
&#xD;
          -  Rifampicin&#xD;
&#xD;
          -  Dihydroergotamine, ergonovine, ergotamine, methylergonovine&#xD;
&#xD;
          -  Cisapride&#xD;
&#xD;
          -  St John's wort&#xD;
&#xD;
          -  Atorvastatin, lovastatin, simvastatin&#xD;
&#xD;
          -  Pimozide&#xD;
&#xD;
          -  Sildenafil or tadalafil&#xD;
&#xD;
          -  Triazolam&#xD;
&#xD;
          -  Presence of contra-indications for antiviral therapy with peginterferon or ribavirin&#xD;
&#xD;
          -  Severe psychiatric disorder, such as major psychoses, suicidal ideation, suicidal&#xD;
             attempt and/or manifest depression.&#xD;
&#xD;
          -  Visual symptoms related to retinal abnormalities&#xD;
&#xD;
          -  Pregnancy, breast-feeding or inadequate contraception&#xD;
&#xD;
          -  Thalassemia, spherocytosis&#xD;
&#xD;
          -  Interfering substance abuse, such as high alcohol intake (indicator: 28 drinks/ week)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A. Boonstra, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Reinier de Graaf Ziekenhuis</name>
      <address>
        <city>Delft</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.gastrolab.nl</url>
    <description>Website of the Department of Gastroenterology &amp; Hepatology - Erasmus Medical Center</description>
  </link>
  <link>
    <url>http://www.erasmusmc.nl</url>
    <description>Website of the Erasmus Medical Center Rotterdam</description>
  </link>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>July 12, 2012</study_first_submitted>
  <study_first_submitted_qc>July 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2012</study_first_posted>
  <last_update_submitted>March 10, 2015</last_update_submitted>
  <last_update_submitted_qc>March 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>Liver</keyword>
  <keyword>Immunology</keyword>
  <keyword>Genotype 1</keyword>
  <keyword>Treatment</keyword>
  <keyword>Chronic</keyword>
  <keyword>RNA Virus Infections</keyword>
  <keyword>Ribavirin</keyword>
  <keyword>Peginterferon alfa-2a</keyword>
  <keyword>Protease Inhibitors</keyword>
  <keyword>Telaprevir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

